Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the ElderlyA Review of Their Efficacy and Safety

被引：0
|
作者：
Beáta J. Radovits
Wietske Kievit
Roland F. J. M. Laan
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Rheumatology
来源：
Drugs & Aging | 2009年 / 26卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Etanercept; Health Assessment Questionnaire Score; Simplify Disease Activity Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Rheumatoid arthritis (RA) is a chronic inflammatory disease that frequently affects people aged ≥65 years, causing significant impairment with pain and functional disability. Elderly RA patients have specific problems, including co-morbid diseases, numerous concomitant medications, greater number of damaged joints as a result of longer disease duration and often a more severe disease presentation in elderly-onset RA. These factors, together with an age-related decline in the immune defence mechanisms, make elderly patients more vulnerable.
引用
收藏
页码：647 / 664
页数：17
相关论文
共 50 条
  • [41] Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
    Campanilho-Marques, Raquel
    Deakin, Claire
    Simou, Stephanie
    Wedderburn, Lucy R.
    Pilkington, Clarissa
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] Safety and Efficacy of the Tumor Necrosis Factor Antagonists
    Bachmann, F.
    Nast, A.
    Sterry, W.
    Philipp, S.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2010, 29 (01) : 35 - 47
  • [43] The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review
    Moots, Robert J.
    Naisbett-Groet, Barbara
    RHEUMATOLOGY, 2012, 51 (12) : 2252 - 2261
  • [44] Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
    Mewar, Devesh
    Wilson, Anthony G.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (04) : 785 - 791
  • [45] Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-α blockers decreases complications?
    Kawakami, Kosei
    Ikari, Katsunori
    Kawamura, Koichiro
    Tsukahara, So
    Iwamoto, Takuji
    Yano, Koichiro
    Sakuma, Yu
    Tokita, Asami
    Momohara, Shigeki
    RHEUMATOLOGY, 2010, 49 (02) : 341 - 347
  • [46] SAFETY AND EFFICACY OF OCRELIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE OR TUMOUR NECROSIS FACTOR INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ahmed, Hussien
    Abushouk, Abdelrahman Ibrahim
    Ismail, Ammar
    Elmaraezy, Ahmed
    Badr, Ahmed Said
    Gadelkarim, Mohamed
    Elnenny, Mohammed
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : A8 - A8
  • [47] Targeting tumour necrosis factor in the treatment of rheumatoid arthritis
    Pearce, GJ
    Chikanza, IC
    BIODRUGS, 2001, 15 (03) : 139 - 149
  • [48] Targeting Tumour Necrosis Factor in the Treatment of Rheumatoid Arthritis
    Glen J. Pearce
    Ian C. Chikanza
    BioDrugs, 2001, 15 : 139 - 149
  • [49] EFFICACY AND SAFETY OF LEFLUNOMIDE OR METHOTREXATE PLUS SUBCUTANEOUS TUMOUR NECROSIS FACTOR-ALPHA BLOCKING AGENTS IN RHEUMATOID ARTHRITIS
    Benucci, M.
    Saviola, G.
    Baiardi, P.
    Manfredi, M.
    Sarzi-Puttini, P.
    Atzeni, F.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2011, 24 (01) : 269 - 274
  • [50] Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
    James R. Spalding
    Joel Hay
    PharmacoEconomics, 2006, 24 : 1221 - 1232
12345